Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758784 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00758784: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT00758784 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00758784, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.
Primary Outcome
Lissamine green staining was assessed for both eyes at each study visit. The Investigator inserted a lissamine green staining strip into the inferior conjunctival cul-de-sac. Staining density for each of the 6 regions of the conjunctiva (temporal, superior temporal, inferior temporal, superior nasal, inferior nasal, and nasal) was graded from 0 to 3 approximately 2.5 minutes after strip instillation according to the National Eye Institute (NEI) chart and grid. The scale for total scoring ranged
Interventions
- DRUG bromfenac ophthalmic solution 0.06%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-08-13 |
| Est. Completion | 2009-01-14 |
| Phase | Phase 2 |
What the finished NCT00758784 record still lists
NCT00758784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which bromfenac ophthalmic solution 0.06% is the first listed.
NCT00758784 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00758784 about?
NCT00758784 is a clinical study titled "Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease". The purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.
What is the current status of trial NCT00758784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2008-08-13. Estimated completion is 2009-01-14.
What interventions are being tested in trial NCT00758784?
The interventions under investigation include: bromfenac ophthalmic solution 0.06% (DRUG).
Who is sponsoring clinical trial NCT00758784?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00758784's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI